You are here

SMSBiotech - Reg S

Overview
Updates (10)
Comments
Contact
This offering has completed and is not accepting investments.
Go to our Home page

We are a San Diego-based biotech company that discovered and named the "SMS" human stem cell. We are the only company currently able to biomanufacture them and develop treatments for horrible diseases like COPD.

What are Small Mobile Stem (SMS) cells?

They are a special type of stem cell that is found natively in our human blood.

 

Icon 1
Ethically obtained from adult human blood

Just two blood vials from one donor will generate trillions of SMS cells that can be applied to many patients.

Icon 2
Extensively safety tested

Both in-vitro and in-vivo testing in multiple animal species show no cellular toxicity or tumour generation.

Icon 3
Massive regenerative performance

SMS cells stimulate regenerative cell growth and show rapid tissue healing in testing.

 

Why are they so special?

Because SMS cells are better in EVERY way than current alternatives.

Non-Immunogenic Anti-inflammatory Multi-targeting Small and fast Easy to administer
bullets
 

How much better?

Mainstream stem cells need to be used within 72hrs to get maximum benefit. SMS cells maintain almost 100% potency at 30 days. This allows them to be transported and stored more efficiently with greater therapeutic effect.

Lifespan & Viability at Standard Refrigeration 2-8°C

how-much
All of these advantages make SMS cells far superior to currently available options.
Invest Now

Creating a path to CURE

Chronic Obstructive Pulmonary Disease

There are 400M active COPD patients worldwide with approximately 3M deaths per year. It was thought to be incurable or irreversible UNTIL NOW.

Main visual
Nebulizer
Administer via NEBULIZER

We are the only technology able to achieve this as no other cells are hearty enough to survive.

Regeneration
Stimulates REGENERATION

SMS cells stimulate growth in lung cells, blood vessel formation, and can regenerate the air sacs.

Recovery
Complete RECOVERY

In our animal studies we saw animal lungs make a complete recovery.

SMS cells DO what NO OTHER treatment can.

Which is why we built a platform.

Our platform is actively producing cell treatments in the areas of COPD and Orthopedics. These treatments are currently limited to use in research and ongoing clinical trials on paths to global commercialization.

Platform Left
Platform Right

Future project areas include:

Neurologic Cardiovascular Organ Disease Oral & Dental Cancer Therapy Cell & Tissue Engineering Longevity
and many more...

Investment Offer Details

Now, there’s a limited-time opportunity for you to join us and help change the meaning of healing.

Valuation
Share Price
Round Size
Minimum Investment
Eligibility
$196.73M
$29 Common Stock
$15.75M
$10,000
Non-US Investors

Qualified Investments Get

Up to
20%
volume based share price discounts available
Limited access to
100%
warrant for cumulative investments of $500k+
Invest Now
Download our investor deck

The Journey So Far

Animal safety studies – completed Q4 ’23 Product development – completed Q4 ’23

Compassionate Use application already filed in US/Internationally with focus on COPD patients

 

Current Roadmap of Clinical Trials

Phase I - 2025

Ongoing, expected to be completed in Q2 2026

Phase II - 2026

Expected to begin in Q2 2026 and complete in Q1 2027

Phase III - 2027

Expected to begin in Q1 2027 and complete in Q4 2027

 

The Future - Ramping Up Production

We are already producing SMS cells and currently have $8M worth of inventory. This year we are adding the first of many planned new manufacturing facilities.

Lab facility
 

Each new facility will allow us to:

Efficiency icon
More Efficiently Produce Cells

Each new facility will allow us to greatly increase production of cells at more efficient cost.

Revenue icon
Generate up to $25M/yr in Revenue per Facility

Every new facility will have modest operating costs that allow us to sell treatments at an estimated 80% + margin.

Demand icon
Get Ahead of Increased Demand

We anticipate increased demand from compassionate use applications, so our ability to produce and store SMS cells now ensures we can meet that demand.

Invest Now
These expansions will allow us to serve a huge global market.

Meet Our Amazing Team

Ghassan Kassab, PhD

Abdulkader Rahmo, PhD

Co-founder, President, Chief Scientific Officer

Bachelors in biochemistry from the Swiss Federal Institute of Technology in Zurich; Ph.D. in Biochemistry from the University of Southern California in Los Angeles. Associate professor, with +30 years of experience in basic and applied research; 12 years primarily focused on SMS cell discovery and development. Experienced in clinical laboratory medicine. Cofounded and lead several private and public entities including the National Commission for Biotechnology. Member of the Board of Directors at California Medical Innovations Institute.

Abdulkader Rahmo, PhD

Ghassan Kassab, PhD

Board Member

Founder/President/CSO of California Medical Innovations Institute in San Diego, Founder of 3DT Holdings (incubator/accelerator of medical devices), and Founder of Acculab Lifesciences. Former professor (in Biomedical Engineering, Surgery, Cellular & Integrative Physiology) at Purdue University. Published over 700 publications and has over 250 issued or pending patents. He sold a major technology and sold four exclusive licenses to the major medical device industry. Board of director member for SMSbiotech.

Harry Friedman

Harry Friedman

CFO, Board of Directors Member at SMSbiotech

Seasoned Businessman, Investor, and Consultant. Experienced Board Member. Self-financed a high-growth technology company that successfully sold, 20-plus years later, to a large conglomerate. Started and participated in growing and selling several technology companies. Was a long-time member of Tech Coast Angels.

Roger Schechter, MD

Roger Schechter, MD

Clinical Research Director at SMSbiotech

FACEP, FCCWS, UHM-ABEM, Medical Director for Wound Management at Palomar Health San Diego, Chief Medical Officer at Synergy Wound Technology, trained in Emergency Medicine, practices full time as a Wound Care and Hyperbaric Medicine Physician, a national level speaker on wound care, advanced wound care modalities, and non-invasive vascular testing.

Jason Kirkness, Ph.D.

Jason Kirkness, Ph.D.

Global Clinical Program Lead – Respiratory at SMSbiotech

A globally recognized medical science executive and pulmonary physiologist with extensive expertise in clinical research, medical device development, and innovation in respiratory medicine. He serves as Chairman of Drug Device Discovery and Development at the American Thoracic Society (ATS), Board of Directors for the ATS and is a member of the RIS Organizing Committee. Previously, he held senior roles at 4DMedical and Fisher & Paykel Healthcare. Has led over 100 clinical trials, secured significant funding from NIH and NHMRC, and authored over 50 high-impact publications. He is an Adjunct Associate Professor at the University of Miami and a former faculty member at Johns Hopkins.

David Schmitt, DVM

David Schmitt, DVM

Veterinary Clinical Research Director at SMSbiotech

A Life Member of the Iowa Veterinary Medical Association (IVMA) with +40 years of service, retired as the Iowa State Veterinarian in 2019 after a distinguished career in both private practice and public service. Served as the State Veterinarian for IDALS, was a key figure in veterinary legislation, has received numerous honors, including Veterinarian of the Year by the IVMA. Served as President of the United States Animal Health Association.

Prof. Peter Wagner, MD

Prof. Peter Wagner, MD

Board of Advisors Member at SMSbiotech

Emeritus Prof. at UCSD, leader in Respiratory Physiology, served as the Pres. of the American Thoracic Society, Pres. of the American Physiological Society, and Division Chief of both Physiology and Pulmonary Critical Care at UCSD School of Medicine, and as both member and chair of National Institutes of Health study sections.

Joe Kiani

Joe Kiani

Board of Directors Member at SMSbiotech

Cofounder of Masimo Corporation; Employing more than 4,250 people worldwide. Kiani and Masimo have more than 595 issued and 310 pending patents worldwide.

Gary Sieck, Ph.D.

Gary Sieck, Ph.D.

Advisor at SMSbiotech

Prof. of Physiology at Mayo Clinic School of Medicine and Science. Studies focus on cell signaling mechanisms that underlie muscle performance, with a focus on regenerative processes that can improve acute and chronic disease conditions. He has published over 380 peer-reviewed papers and received multiple NIH grants over 37+ years.

Prof. James Sherley, MD

Prof. James Sherley, MD

Board of Advisors Member at SMSbiotech

Former Associate professor at MIT (nine years), founder and former director of the Adult Stem Cell Technology Center at the Boston Biomedical Research Institute (5yrs); currently SMSbiotech board of advisor member, founder, and Director of Asymmetrex, LLC, Adjunct Associate Professor, Hematology-Oncology Department, Rhode Island Hospital Brown University.

Updates

December 03
SMSbiotech Presents at the 5th International Webinar on Orthopedics in Paris, France

Watch SMSbiotech’s Presentation from the 5th International Orthopedics Webinar

We are pleased to share an important update from SMSbiotech’s recent participation in the 5th International Webinar on Orthopedics, Osteoporosis, and Musculoskeletal Disorders, held virtually from Paris, France on November 26–27, 2025.

On November 27, Dr. Abdulkader Rahmo delivered a featured presentation titled: “Small Mobile Stem (SMS) Cell Treatment Prospects for Orthopaedic Diseases.” This session introduced the global orthopedic community to the unique characteristics and therapeutic potential of Small Mobile Stem (SMS) cells, a novel class of regenerative cells distinct from traditional mesenchymal stem cells.

Watch the full presentation:

SMSbiotech Presents at the 5th International Webinar on Orthopedics in Paris, France

Thank you for your continued support as we advance the science and real-world impact of regenerative cell therapy.

November 12
SMSbiotech recognized by the European Society of Medicine

We are pleased to announce that the European Society of Medicine has published a new peer-reviewed article highlighting the transformative potential of Small Mobile Stem (SMS) cells—a discovery that could redefine the future of regenerative medicine.

Authored by Dr. Abdulkader Rahmo, President and Chief Science Officer at SMSbiotech, the article—“Small Mobile Stem Cells: A Transformative Paradigm for Regenerative Medicine”—appears in the Medical Research Archives (Volume 13, Issue 10).

Published under open access, this work presents SMS cells as a novel class of “intelligent messenger” stem cells capable of sensing their environment, coordinating targeted repair, and restoring tissue function across multiple organ systems. By introducing the concept of regenerative intelligence, this research highlights a new biological framework that integrates immune modulation, tissue regeneration, and adaptive healing.

“These findings represent a shift from traditional stem cell therapies toward a more dynamic, self-regulating model of tissue restoration,” said Dr. Rahmo.

This publication by the European Society of Medicine underscores growing international recognition of SMS cell research and its potential to advance regenerative science and clinical applications.

Read the full publication:

Small Mobile Stem Cells: A Transformative Paradigm for Regenerative Medicine

November 05
SMSbiotech Expands with New San Diego Bio-Manufacturing Facility

We are excited to share that in addition to our existing biomanufacturing facility—where we have developed and tested our proprietary SMS Stem cell manufacturing system—SMSbiotech is currently establishing and preparing a new, much larger state-of-the-art biomanufacturing lab facility in San Diego. This facility is expected to be fully operational within the next 2–3 months and will play a critical role in scaling up our clinical programs, providing expanded access to our partners for clinical trials and compassionate use initiatives, and supporting ongoing research.

The new lab features multiple ISO 7 certified cleanrooms and is equipped with top-of-the-line systems, including centrifuges, biological safety hoods, and other specialized equipment. These enhancements will significantly expand our capacity to produce high-quality SMS cells at scale while maintaining rigorous safety and quality standards. This ensures readiness for upcoming clinical milestones and reinforces our commitment to excellence in regenerative therapy production.

This expansion represents a major step forward in SMSbiotech’s mission to advance regenerative therapies and bring innovative solutions to patients. Stay tuned for further updates as we move toward completion and operational readiness.

October 29
Regenerative Breakthrough in Canine Wound Healing

Unexpected Systemic Benefits of SMS Cell Therapy Demonstrate Broad Regenerative Potential

SMSbiotech is pleased to share a compelling outcome from its ongoing work with Small Mobile Stem (SMS) cells in companion animals.

Baji, a 13-year-old Australian Cattle Dog suffering from severe arthritis and neurodegenerative weakness, received intravenous SMS cell therapy to support joint and mobility recovery. Unexpectedly, clinicians observed dramatic healing in an unrelated paw wound that had reached the bone and carried a high risk of amputation.

Within one week of systemic SMS cell administration, the wound site exhibited rapid granulation, new tissue formation, and clear signs of recovery. The wound continued to heal steadily, and amputation was no longer required.

This outcome illustrates that SMS cells, when administered intravenously, can home to distant injury sites, modulate inflammation, and stimulate endogenous repair mechanisms, demonstrating both local and systemic regenerative effects.

From an innovation and market opportunity standpoint, this case provides a powerful proof-of-concept for SMSbiotech’s platform:

  • Broad Veterinary Application: SMS therapy could address complex, hard-to-heal wounds in companion animals—an unmet need in veterinary care.
  • Non-Surgical Regenerative Solution: Potential to reduce reliance on invasive procedures such as amputation or reconstructive surgery.
  • Scalable Translational Value: The mechanism of systemic wound healing has direct implications for human chronic wound and tissue repair markets, including diabetic ulcers, pressure injuries, and trauma recovery.

Baji’s recovery offers compelling early validation of SMSbiotech’s core technology, supporting its strategy to advance systemic, minimally invasive regenerative therapies across both veterinary and human medicine.

October 22
SMSbiotech Advances Phase 1 COPD Clinical Trial in Australia

We are pleased to share a significant milestone in SMSbiotech’s ongoing human Phase 1 clinical trial for COPD, currently being conducted in Australia by Veritus Research.

As part of the study’s initial safety evaluation, the first two sentinel patients received their scheduled administrations on July 11th and July 18th, respectively. Both patients successfully completed their dosing and observation periods under close clinical supervision in accordance with the study protocol. We are pleased to report that both patients responded well, with no adverse effects or reactions related to the drug.

These encouraging results represent an important step forward in confirming the safety profile of SMSbiotech’s nebulized cell therapy platform, which will soon be applied to multiple other chronic indications. This marks a strong start to our first-in-human study and underscores the potential of our regenerative approach in addressing chronic diseases such as COPD.

We extend our sincere appreciation to our advisors, clinical partners, principal investigators, monitors, coordinators, and the research team at Veritus, as well as to our supporters for their continued confidence in SMSbiotech’s mission to advance breakthrough cell therapies.

Clinical Trial Registration:
ACTRN12624001140549p
Registered with ClinicalTrials.gov and the Australian New Zealand Clinical Trials Registry (ANZCTR).

October 15
New Clinical Animal Study Demonstrates SMS Cell Therapy’s Regenerative Power

Our team recently completed a clinical animal study using our human Small Mobile Stem (SMS) cell platform in horses suffering from tendon injuries—conditions that closely mirror human orthopedic challenges.

In collaboration with leading veterinarians, six horses with diverse orthopedic pathologies—including tendon tears, joint cartilage degeneration, and chronic lameness—were treated with our patented SMS cells.

The study demonstrated remarkable tendon repair, with evidence of restored tissue structure and function across multiple treated horses.

Our recent case summaries and veterinary evaluations reveal:

  • Significant recovery in severe joint and tendon injuries – Horses with conditions equivalent to human OCD (osteochondritis dissecans) and chronic tendinopathy experienced dramatic functional improvement and pain reduction.
  • Reduced medication dependence – Horses previously reliant on daily NSAIDs required little to none following treatment.
  • Enhanced healing and overall vitality – Post-treatment evaluations demonstrated visible tendon regeneration, improved balance, and restored exercise performance.

These results highlight the regenerative potential of SMS cells for musculoskeletal injuries, supporting not only future veterinary applications but also the broader translational promise of our platform for human tendon and orthopedic indications.

This successful study further strengthens our confidence in the versatility of the SMS technology and marks another important step in expanding our development pipeline.

Comments

Post comment

PPM

active campaign